PD-1 x IL-2Rα (IL2RA)

Class

PD-1/IL-2-alpha-biased bispecific fusion protein (immunocytokine)

Pathway

PD-1 immune checkpoint blockade combined with biased IL-2 receptor agonism to enhance anti-tumor T-cell responses while limiting IL-2 toxicity

This mechanism combines two distinct immune-modulating actions in a single bispecific fusion protein: blockade of programmed cell death protein 1 (PD-1), an inhibitory receptor on T cells that tumors exploit to suppress immune attack, and biased agonism of the interleukin-2 receptor alpha subunit (IL-2Rα, also called CD25), part of the receptor complex for the cytokine IL-2, which drives T-cell proliferation and effector function. Blocking PD-1 removes a brake on T-cell activity, while the IL-2 component supplies a proliferative and activating signal. Native IL-2 therapy is limited because it broadly activates any cell bearing IL-2 receptors, including regulatory T cells (which dampen immune responses) and vascular endothelial cells (causing fluid leakage into tissues, a toxicity called vascular leak syndrome). By fusing the IL-2 signaling function to an anti-PD-1 targeting arm and biasing its receptor engagement, this molecule aims to concentrate cytokine activity on PD-1-expressing, tumor-engaged T cells rather than triggering systemic cytokine effects. This dual-mechanism approach is being explored broadly across solid tumors where checkpoint blockade alone is insufficient and where added T-cell expansion could improve anti-tumor responses without the systemic toxicity historically limiting IL-2-based therapies.